Aktienanalyse zu Nektar Therapeutics (NKTR)NKTRNektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nektar Therapeutics is not a good buy right now due to its extremely low RSI of 16.77, indicating oversold conditions, and a significant 5-day price drop of 13.09%. Additionally, the stock's forward P/E ratio is high at 34.01, suggesting overvaluation relative to its earnings potential. The company faces legal risks and has seen a 1229.84% increase in hedge fund selling activity, which raises concerns about investor confidence.

11 analysts cover NKTR: 10 rate it Buy, 1 Hold and 0 Sell. The average price target is 123.43.